Examination of changes in utilization, dose adequacy, and duration associated with market entry of the oral chelator deferasirox as a potential substitute for parenteral deferoxamine.
Maria R. Baer, MD
Advertisement
Articles by Maria R. Baer, MD
Advertisement
Latest Updated Articles
- Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies
Published: March 17th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
UConn’s Medical Writing Certificate Program: It’s Just "Write"
3
Pharmacy Policy Updates for October 2025
4
TACTI-004 Trial Studying Eftilagimod Alfa With Pembrolizumab in Advanced NSCLC to Begin Evaluation
5
